FibroGen Inc [NASDAQ: FGEN] plunged by -$0.69 during the normal trading session on while it closed the day at $1.47. The company report on April 2, 2024 at 5:46 PM that FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with
FibroGen Inc [NASDAQ: FGEN] gained 9.68% or 0.21 points to close at $2.38 with a heavy trading volume of 4046853 shares. The company report on February 5, 2024 at 7:00 AM that FibroGen To Host Part I of Virtual KOL Investor Event Series to Review
FibroGen Inc [NASDAQ: FGEN] gained 82.71% on the last trading session, reaching $1.71 price per share at the time. The company report on January 25, 2024 at 7:00 AM that FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase
© 2024, Powered by Smart TechOne
